ALRN News and Press, Aileron Therapeutics Inc. From 11/12/21

Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy Updated planned NSCLC study data readouts include interim results in 2Q22; topline full results in 4Q2...

Today, we take an in-depth look at a small biotech concern that is very deep in 'Busted IPO' territory. The company is focused on developing a treatment to reduce the negative symptoms of chemotherapy. A full investment analysis is presented in the paragraphs. For further de...

-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agent for patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924’s activation of p21-induced cell cycle arrest in murine bone marro...

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced it will present new preclinical data at the upcoming AACR-NCI-EORTC In...

Final results from completed Phase 1b trial in patients with small cell lung cancer (SCLC) receiving second-line topotecan demonstrated ALRN-6924’s ability to reduce neutropenia, thrombocytopenia and anemia caused by chemotherapy, as well as the need for transfusions Prelimin...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Preliminary findings from ongoing Phase 1 healthy volunteer study will include data relating to mechanism of action; optimal dose; and time to onset, duration and magnitude of pharmacodynamic effects Final data from completed Phase 1b study in patients with small cell lung cancer (S...

Barron's spoke with investors and an analysts who focus on the biotech field to find names that are poised to make a comeback. Many biotech stocks have had a tough year so far. The SPDR Biotech ETF (NYSEARCA:XBI) is down 4.7% year-to-date. That compares to a 20.8% return in the same period fo...

Initial findings from an ongoing study demonstrated that a 0.3 mg/kg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in normal bone marrow cells in healthy volunteers Aileron is currently conducting a Phase 1b ran...

Locust Walk Acquisition LWACU +235% and eFFECTOR Therapeutics announce business combination Pop Culture (NASDAQ:CPOP) +26% develop street dance chain SaaS system to accelerate digital transformation Jiayin Group (NASDAQ:JFIN) +18% on Q2 earnings. Astrotech (NASDAQ:ASTC) +1...